Egetis Therapeutics AB (publ) (STO: EGTX)
Sweden
· Delayed Price · Currency is SEK 5.50
+0.07 (1.29%)
Nov 21, 2024, 9:12 AM CET
Egetis Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 67.9 | 57.6 | 22.6 | 38.2 | 40.66 | 82.56 | Upgrade
|
| Revenue | 67.9 | 57.6 | 22.6 | 38.2 | 40.66 | 82.56 | Upgrade
|
| Revenue Growth (YoY) | 121.17% | 154.87% | -40.84% | -6.05% | -50.75% | 192.66% | Upgrade
|
| Cost of Revenue | 207.5 | 204.5 | 142.6 | 96.6 | 185.17 | 112.24 | Upgrade
|
| Gross Profit | -139.6 | -146.9 | -120 | -58.4 | -144.51 | -29.68 | Upgrade
|
| Selling, General & Admin | 196.1 | 169.8 | 74.3 | 44.6 | 32.15 | 36.72 | Upgrade
|
| Other Operating Expenses | -3.7 | - | - | -0.3 | - | - | Upgrade
|
| Operating Expenses | 163.8 | 173.4 | 77 | 46.8 | 32.55 | 36.93 | Upgrade
|
| Operating Income | -303.4 | -320.3 | -197 | -105.2 | -177.06 | -66.61 | Upgrade
|
| Interest Expense | -24.1 | -4.1 | -0.1 | -0.2 | -0 | -0.01 | Upgrade
|
| Interest & Investment Income | 12.5 | 4.9 | 0.9 | 0.1 | 0.16 | 5.27 | Upgrade
|
| Currency Exchange Gain (Loss) | -4.6 | -4.6 | 2.4 | 0.6 | -1.13 | -0.07 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.4 | -2.7 | - | 0.2 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -319.2 | -326.8 | -193.8 | -104.5 | -178.02 | -61.42 | Upgrade
|
| Pretax Income | -319.2 | -326.8 | -193.8 | -104.5 | -178.02 | -61.42 | Upgrade
|
| Income Tax Expense | 0.1 | 0.1 | - | - | - | - | Upgrade
|
| Net Income | -319.3 | -326.9 | -193.8 | -104.5 | -178.02 | -61.42 | Upgrade
|
| Net Income to Common | -319.3 | -326.9 | -193.8 | -104.5 | -178.02 | -61.42 | Upgrade
|
| Shares Outstanding (Basic) | 291 | 257 | 194 | 180 | 67 | 52 | Upgrade
|
| Shares Outstanding (Diluted) | 291 | 260 | 194 | 180 | 67 | 52 | Upgrade
|
| Shares Change (YoY) | 29.11% | 33.86% | 7.97% | 166.96% | 30.54% | 6.08% | Upgrade
|
| EPS (Basic) | -1.10 | -1.27 | -1.00 | -0.58 | -2.64 | -1.19 | Upgrade
|
| EPS (Diluted) | -1.12 | -1.30 | -1.00 | -0.60 | -2.64 | -1.20 | Upgrade
|
| Free Cash Flow | -216 | -278.4 | -173.5 | -130.3 | -134.66 | -62.64 | Upgrade
|
| Free Cash Flow Per Share | -0.74 | -1.07 | -0.89 | -0.72 | -2.00 | -1.21 | Upgrade
|
| Gross Margin | -205.60% | -255.03% | - | -152.88% | - | -35.95% | Upgrade
|
| Operating Margin | -446.83% | -556.08% | -871.68% | -275.39% | -435.43% | -80.68% | Upgrade
|
| Profit Margin | -470.25% | -567.53% | -857.52% | -273.56% | -437.81% | -74.40% | Upgrade
|
| Free Cash Flow Margin | -318.11% | -483.33% | -767.70% | -341.10% | -331.18% | -75.87% | Upgrade
|
| EBITDA | -299.8 | -316.7 | -195.8 | -104 | -176.88 | -66.4 | Upgrade
|
| EBITDA Margin | - | - | - | -272.25% | - | -80.42% | Upgrade
|
| D&A For EBITDA | 3.6 | 3.6 | 1.2 | 1.2 | 0.18 | 0.21 | Upgrade
|
| EBIT | -303.4 | -320.3 | -197 | -105.2 | -177.06 | -66.61 | Upgrade
|
| EBIT Margin | - | - | - | -275.39% | - | -80.68% | Upgrade
|
| Revenue as Reported | 57.6 | 57.6 | 22.6 | 38.5 | 40.66 | 82.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.